Skip to main content

Advertisement

Table 2 Awaiting FDA approval

From: Potential new targets for drug development in severe asthma

  Mechanism of Action Biomarker Outcomes Significant Adverse Events References
Dupilumab (Completed phase III, under FDA review) Anti-IL4R ↑Peripheral eosinophils (≥300/uL)
↑Sputum eosinophils (≥3%)
Decreased exacerbations and symptoms
Improved FEV1
Decreased glucocorticoid use
Decreased
FeNO